Brief: Poxel Initiates Phase 2A Program For Pxl770 For Treatment Of Nash

Poxel SA

01/04/2019 07:07

April 1 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL INITIATES PHASE 2A PROGRAM FOR PXL770, A DIRECT AMPK
ACTIVATOR FOR THE TREATMENT OF NASH
    * PHASE 2A EFFICACY AND SAFETY STUDY FOR PXL770 IS UNDERWAY
WITH
DATA RESULTS ANTICIPATED 1H 2020
    * PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) STUDY FOR PXL770
IS
EXPECTED TO INITIATE 2Q 2019 WITH RESULTS ANTICIPATED 2H 2019

Source text for Eikon:  urn:newsml:reuters.com:*:nBw7McjyWa
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))